| 产品描述: | Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function. |
| 体外研究: |
Soquelitinib (30 mg/kg, 口服强饲, 一天两次, 持续 20 天) 增强 CD8T 细胞的浸润,提高肿瘤浸润淋巴细胞 (TILs) 的细胞溶解能力,并增强在 CT26 肿瘤模型中抗 PD1 和抗 CTLA4 的疗效[1]。 |
| 体内研究: |
Soquelitinib (10 μM, 2 小时) 在 Jurkat 细胞中抑制 ITK 下游的 TCR 信号传导,并阻止 IL-2 的产生。 Soquelitinib (10 μM, 1 小时) 在 CD4 T 细胞中抑制与 Th2 相关的细胞因子并诱导 Th1 偏移。 |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.943 ml |
9.715 ml |
19.43 ml |
| 5 mM |
0.389 ml |
1.943 ml |
3.886 ml |
| 10 mM |
0.194 ml |
0.972 ml |
1.943 ml |
| 50 mM |
0.039 ml |
0.194 ml |
0.389 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |